Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 10Burkitt Lymphoma 9Lymphoma, Mantle-Cell 6Leukemia, Biphenotypic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Recurrence 3Myeloproliferative Disorders 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Down Syndrome 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Complete Response 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms 1

Interventions

fludarabine phosphate 1fludarabine 1Cytarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Blastic Plasmacytoid Dendritic Cell Neoplasm × Cytarabine × Clear all
NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Senti Biosciences

Phase 1 Active not recruiting
21 enrolled
MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡